Global Antifungal Drugs Market 2017-2021

  • ID: 4115365
  • Report
  • Region: Global
  • 91 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Allergan
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Meiji Seika Pharma
  • Novan
  • Seren Pharmaceuticals
  • MORE
About Antifungal Drugs

Antifungal drugs are chemical compounds used to kill or inhibit the growth of fungi. These drugs act by various mechanisms such as the inhibition of cell division, the inhibition of cell wall formation, and cell membrane disruption.

The analysts forecast the global antifungal drugs market to grow at a CAGR of 3.20% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global antifungal drugs market for 2017-2021. To calculate the market size, the report considers revenue generated from the sales of branded, generics and OTC drugs used for the treatment and prevention of various fungal infections. The report also considers the revenue to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenue from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Antifungal Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Pfizer
- Merck
- Astellas Pharma
- Novartis
- Johnson & Johnson

Other prominent vendors
- Allergan
- Almirall
- Amgen
- Aqua Pharmaceuticals
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Celgene
- Dermira
- Elorac
- F. Hoffmann-La Roche
- Galderma
- Genentech
- GlaxoSmithKline
- Hexima
- Hisamitsu Pharmaceutical
- Incyte
- Mayne Pharma
- MediQuest Therapeutics
- Meiji Seika Pharma
- Merz Pharmaceuticals
- Moberg Pharma
- Mylan Pharmaceuticals
- NanoBio
- NovaBiotics
- Novan
- Nuvo Research
- Polichem
- Promius Pharma
- Sanofi
- Seren Pharmaceuticals
- Sun Pharma
- Taro
- Teva Pharmaceutical
- Theravance Biopharma
- Topica Pharmaceuticals
- Viamet Pharmaceuticals

Market drivers
- Rising popularity of OTC antifungal drugs for dermal infections
- For a full, detailed list, view the full report

Market challenges
- Antifungal drug resistance
- For a full, detailed list, view the full report

Market trends
- Increased funding for antifungal research
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Meiji Seika Pharma
  • Novan
  • Seren Pharmaceuticals
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: Market landscape

Market overview

Five forces analysis

PART 06: Market segmentation by ROA

Global oral antifungal drugs market

Global parenteral antifungal drugs market

Global topical antifungal drugs market

PART 07: Market segmentation by type

Global prescription antifungal drugs market

Global OTC antifungal drugs market

PART 08: Market segmentation by chemical class

PART 09: Geographical segmentation

Antifungal drugs market in Americas

Antifungal drugs market in the US

Antifungal drugs market in EMEA

Antifungal drugs market in Europe

Antifungal drugs market in APAC

Antifungal drugs market in Japan

PART 10: Market drivers

QIDP and other special regulatory designations

Increase in prevalence of infections and environmental changes

Rising popularity of OTC antifungal drugs for dermal infections

PART 11: Impact of drivers

PART 12: Market challenges

Antifungal drug resistance

Increased availability of generics and alternative therapies

Poor patient adherence

PART 13: Impact of drivers and challenges

PART 14: Market trends

Increased funding for antifungal research

Increased focus on combination therapies

Incorporation of novel technology for product development

Strategic alliances and M&A

PART 15: Vendor landscape

Competitive scenario

Other prominent vendors

PART 16: Key vendor analysis

Astellas Pharma

Johnson & Johnson

Merck

Novartis

Pfizer

PART 17: Appendix

List of abbreviations

PART 18: About the Author

List of Exhibits
Exhibit 01: Market snapshot of global antifungal drugs market
Exhibit 02: Overview of global antifungal drugs market 2016-2021
Exhibit 03: Global antifungal drugs market snapshot: Developed and emerging markets 2016-2021
Exhibit 04: Global antifungal drugs market 2016-2021 ($ billions)
Exhibit 05: Opportunity analysis in global antifungal drugs market
Exhibit 06: Impact of factors affecting the market 2016 and 2021
Exhibit 07: Impact of key customer segments on global antifungal drugs market 2016
Exhibit 08: Five forces analysis
Exhibit 09: Share of global antifungal drugs by ROA 2016 and 2021
Exhibit 10: Market overview of global oral antifungal drugs market
Exhibit 11: Market overview of global parenteral antifungal drugs market
Exhibit 12: Market overview of global topical antifungal drugs market
Exhibit 13: Global antifungal drugs market segmentation by type 2016
Exhibit 14: Market overview of global prescription antifungal drugs market
Exhibit 15: Market overview of global OTC antifungal drugs market
Exhibit 16: Types of anti-fungal drugs by chemical class
Exhibit 17: Global antifungal drugs market: Segmentation by geography (2016-2021)
Exhibit 18: Global antifungal drugs market segmentation by region: Market growth lifecycle analysis 2016
Exhibit 19: Overview of antifungal drugs market in Americas
Exhibit 20: Antifungal drugs market in Americas 2016-2021 ($ billions)
Exhibit 21: Opportunity analysis in antifungal drugs market in Americas
Exhibit 22: Overview of antifungal drugs market in the US
Exhibit 23: Overview of antifungal drugs market in EMEA
Exhibit 24: Antifungal drugs market in EMEA 2016-2021 ($ billions)
Exhibit 25: Opportunity analysis in antifungal drugs market in EMEA
Exhibit 26: Overview of antifungal drugs market in Europe
Exhibit 27: Overview of antifungal drugs market in APAC
Exhibit 28: Antifungal drugs market in APAC 2016-2021 ($ billions)
Exhibit 29: Opportunity analysis in antifungal drugs market in APAC
Exhibit 30: Overview of antifungal drugs market in Japan
Exhibit 31: Impact of drivers and challenges on global antifungal drugs market
Exhibit 32: Impact of drivers
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Impact of trends in global antifungal drugs market
Exhibit 35: Competitive structure analysis of global antifungal drugs market 2016
Exhibit 36: Competitive analysis of global antifungal drugs market
Exhibit 37: Market penetration of various antifungal drug makers worldwide 2016
Exhibit 38: Astellas Pharma: Key highlights
Exhibit 39: Astellas Pharma: Strength assessment
Exhibit 40: Astellas Pharma: Strategy assessment
Exhibit 41: Astellas Pharma: Opportunity assessment
Exhibit 42: Johnson & Johnson: Key highlights
Exhibit 43: Johnson & Johnson: Strength assessment
Exhibit 44: Johnson & Johnson: Strategy assessment
Exhibit 45: Johnson & Johnson: Opportunity assessment
Exhibit 46: Merck: Key highlights
Exhibit 47: Merck: Strength assessment
Exhibit 48: Merck: Strategy assessment
Exhibit 49: Merck: Opportunity assessment
Exhibit 50: Novartis: Key highlights
Exhibit 51: Novartis: Strength assessment
Exhibit 52: Novartis: Strategy assessment
Exhibit 53: Novartis: Opportunity assessment
Exhibit 54: Pfizer: Key highlights
Exhibit 55: Pfizer: Strength assessment
Exhibit 56: Pfizer: Strategy assessment
Exhibit 57: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allergan
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Meiji Seika Pharma
  • Novan
  • Seren Pharmaceuticals
  • MORE
New Report Released: – Global Antifungal Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global antifungal drugs market: Pfizer, Merck, Astellas Pharma, Novartis, and Johnson & Johnson.

Other Prominent Vendors in the market are: Allergan, Almirall, Amgen, Aqua Pharmaceuticals, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dermira, Elorac, F. Hoffmann-La Roche, Galderma, Genentech, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Incyte, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharmaceuticals, Moberg Pharma, Mylan Pharmaceuticals, NanoBio, NovaBiotics, Novan, Nuvo Research, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Sun Pharma, Taro, Teva Pharmaceutical, Theravance Biopharma, Topica Pharmaceuticals, and Viamet Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is increased funding for antifungal research. Currently, few companies are investing in the discovery and R&D of drugs for these infections. This can be attributed to the increased regulatory guidelines and the decreased profits available for the development of antifungal drugs.”

According to the report, one of the major drivers for this market is rising popularity of OTC antifungal drugs for dermal infections. Many OTC products or cosmeceuticals are available in the market for the treatment of dermal infections. Extensive advertisements and endorsements of OTC products have increased their sales over prescription drugs. OTC products are cost-effective in nature compared to their branded counterparts.

Further, the report states that one of the major factors hindering the growth of this market is antifungal drug resistance. The development of multidrug resistant microbes is one of the major threats to the human health in the present days. The microbe changes itself to protect against the antimicrobial agent used and thereby develops resistance to the drug. This develops primarily due to the irrational use of drugs. The incorrect prescription of the drugs by the physicians or the incorrect dosing or course taken by the patients along with the increased use in agriculture and animal husbandry industry leads to the development of such resistance.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Pfizer
  • Merck
  • Astellas Pharma
  • Novartis
  • Johnson & Johnson
  • Allergan
  • Almirall
  • Amgen
  • Aqua Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Celgene
  • Dermira
  • Elorac
  • F Hoffmann-La Roche
  • Galderma
  • Genentech
  • GlaxoSmithKline
  • Hexima
  • Hisamitsu Pharmaceutical
  • Incyte
  • Mayne Pharma
  • MediQuest Therapeutics
  • Meiji Seika Pharma
  • Merz Pharmaceuticals
  • Moberg Pharma
  • Mylan Pharmaceuticals
  • NanoBio
  • NovaBiotics
  • Novan
  • Nuvo Research
  • Polichem
  • Promius Pharma
  • Sanofi
  • Seren Pharmaceuticals
  • Sun Pharma
  • Taro
  • Teva Pharmaceutical
  • Theravance Biopharma
  • Topica Pharmaceuticals
  • Viamet Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll